Yasmin A Lyons

Dr. Yasmin A Lyons


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
NCNicholas Cardillo
Nicholas Cardillo
DRDouglas Russo
Douglas Russo
ANAndreea Newtson
Andreea Newtson
HRHenry Reyes
Henry Reyes
YLYasmin A Lyons
Yasmin A Lyons
JBJesus Gonzalez Bosquet
Jesus Gonzalez Bosquet
Long non-coding RNA’s (lncRNA) are RNA sequences that do not encode proteins and are greater than 200 nucleotides in length. They regulate complex cellular mechanisms and have been associated with prognosis in various types of cancer. We aimed to identify lncRNA sequences that are associated with high grade serous ovarian cancer (HGSC) and assess their impact on overall survival. RNA was extracted from 112 HGSC patients and 12 normal fallopian tube samples from our Biobank tissue repository. RNA was sequenced and the Ultrafast and Comprehensive lncRNA detection and quantification pipeline (UClncR) was used for the identification of lncRNA sequences. Univariate logistic and multivariate lasso regression analyses identified lncRNA that was associated with HGSC. Univariate and multivariate Cox proportional hazard ratios were used to evaluate independent predictors of survival. 1943 of 16,325 investigated lncRNA’s were differentially expressed in HGSC as compared to controls (p < 0.001). Nine of these demonstrated association with cancer after multivariate lasso regression. Our multivariate analysis of survival identified four lncRNA’s associated with survival in HGSC. Three out of these four were found to be independently significant after accounting for all clinical covariates. Lastly, seven lncRNAs were independently associated with initial response to chemotherapy; four portended a worse response, while three were associated with improved response. More research is needed, but there is potential for these lncRNAs to be used as biomarkers of HGSC or predictors of treatment outcome in the future.

1 June 2026 in Annals of Lymphoma
Verified
Journal Article
Open access
PDF file
ATAnnemarie Thompson
Annemarie Thompson
CSClaire M. Schenken
Claire M. Schenken
JAJulia Armstrong
Julia Armstrong
NSNicole M. Spencer
Nicole M. Spencer
LBLeyla Bojanini
Leyla Bojanini
YLYasmin A Lyons
Yasmin A Lyons
Background: Peritoneal lymphomatosis is a rare manifestation of non-Hodgkin’s lymphoma in which the lymphoma seeds the peritoneum. Peritoneal lymphomatosis can be seen with aggressive/high-grade B-cell lymphomas such as diffuse large B-cell lymphoma, or, more rarely, Burkitt lymphoma. More commonly, ovarian or gastrointestinal malignancies metastasize to the peritoneum as peritoneal carcinomatosis that closely mimics peritoneal lymphomatosis. Case Description: We report a case of a 45-year-old female who presented with abdominal distension and computed tomography (CT) findings suggestive of peritoneal carcinomatosis. She underwent inconclusive paracentesis, CT-guided omental biopsy, esophagogastroduodenoscopy and colonoscopy. She was ultimately diagnosed with peritoneal lymphomatosis secondary to Burkitt lymphoma by laparoscopic-directed omental biopsies. Burkitt lymphoma was confirmed by flow cytometry and fluorescence in situ hybridization (FISH) showing IGH::MYC t(8;14). Following diagnosis, she received one cycle of chemotherapy DA-EPOCH-R (rituximab, doxorubicin, etoposide, vincristine, cyclophosphamide, prednisone). She was subsequently diagnosed with central nervous system involvement and underwent intrathecal and systemic methotrexate followed by two cycles of R-IVAC (rituximab, ifosfamide, etoposide, cytarabine) and one cycle of R-CODOX-M (rituximab, cyclophosphamide, vincristine, doxorubicin, methotrexate). She had no evidence of disease on PET imaging 6 months after treatment. Conclusions: Because imaging findings of peritoneal carcinomatosis and peritoneal lymphomatosis often overlap, prompt tissue biopsy is essential to guide management, as peritoneal lymphomatosis is treated with chemotherapy alone, while peritoneal carcinomatosis often requires surgical debulking and misdiagnosis may result in unnecessary surgery.

1 May 2021 in Gynecologic Oncology Reports
Verified
Journal Article
Open access
LBLogan Blankenship
Logan Blankenship
YLYasmin A Lyons
Yasmin A Lyons
HCHaisar Dao Campi
Haisar Dao Campi
PVPhilip T. Valente
Philip T. Valente
LBLaura Barnes
Laura Barnes
EKEdward R. Kost
Edward R. Kost
• Rectovaginal septum mass in BRCA1 positive patient after risk reducing BSO years prior. • Papillary serous carcinoma presenting as a rectovaginal septum mass. • PAOLA-1 trial discussion for rectovaginal septum mass in BRCA1 positive patient.

30 September 2025 in Biomolecules
Verified
Journal Article
Open access
PDF file
WAWilliam C. Arnold
William C. Arnold
DPDurga Meenakshi Panneerdoss
Durga Meenakshi Panneerdoss
BSBaskaran Subramani
Baskaran Subramani
MMMegharani Mahajan
Megharani Mahajan
BEBehnam Ebrahimi
Behnam Ebrahimi
YLYasmin A Lyons
Yasmin A Lyons
Ovarian cancer (OCa) remains the most lethal gynecologic malignancy in the United States, with low-grade serous and mucinous subtypes frequently driven by KRAS mutations. These mutations activate downstream MAPK and PI3K/AKT signaling pathways, contributing to tumor progression and resistance to therapy. Although the MEK inhibitor trametinib is used to target these pathways, its efficacy is limited in KRAS-mutant OCa due to compensatory activation of the leukemia inhibitory factor (LIF)/LIF receptor (LIFR) axis. In this study, we evaluated the therapeutic potential of combining trametinib with EC359, a selective LIFR inhibitor, in Ras/Raf-driven OCa models. EC359 significantly reduced cell viability, clonogenic survival, and induced cell death via ferroptosis in vitro. Mechanistic studies revealed that EC359 suppressed trametinib-induced activation of LIFR downstream signaling. RNA-seq analysis showed that combination therapy downregulated mitochondrial translation and MYC target genes while upregulating apoptosis-related genes. In vivo, EC359 and trametinib co-treatment significantly reduced tumor growth in xenograft and PDX models without inducing toxicity. Our studies identify LIFR signaling as a critical vulnerability in Ras/Raf-mutant and low grade serous OCa. Further, it provides strong preclinical rationale for EC359 and trametinib combination therapy as a new therapeutic strategy for treating Ras/Raf-driven OCa and low-grade serous OCa.

11 August 2026 in Journal of Medical Case Reports
Verified
Journal Article
Open access
PDF file
RHRose Ann Huynh
Rose Ann Huynh
YLYasmin A Lyons
Yasmin A Lyons
GMGeorgia A. McCann
Georgia A. McCann
PVPhilip T. Valente
Philip T. Valente
KHKevin L. Hall
Kevin L. Hall
EKEdward R. Kost
Edward R. Kost
Reports describing the concurrent management of adult-type granulosa cell tumor (AGCT) and chronic limb-threatening ischemia (CLTI) are exceedingly rare, h